Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Rebecca Liu & Kyle Staller. (2020) Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives. Drug Design, Development and Therapy 14, pages 1391-1400.
Read now
Read now
Scott Bleser. (2011) Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes. Current Medical Research and Opinion 27:3, pages 503-512.
Read now
Read now
Articles from other publishers (19)
Sudheesh T. Sivanandan, Diksha Chauhan & Irishi N. N. Namboothiri. (2022) One‐Pot Regio‐ and Diastereoselective Synthesis of Tetrahydro‐α‐carbolines via Cascade Reactions of Iminoindolines with Morita‐Baylis‐Hillman Bromides of Nitroalkenes. European Journal of Organic Chemistry 2022:3.
Crossref
Crossref
T. Louwies & B. Greenwood-Van Meerveld. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
132
163
.
Christopher Tait & Gregory S. Sayuk. (2021) The Brain-Gut-Microbiotal Axis: A framework for understanding functional GI illness and their therapeutic interventions. European Journal of Internal Medicine 84, pages 1-9.
Crossref
Crossref
Daniel Hoyer. (2020) Targeting the 5-HT system: Potential side effects. Neuropharmacology 179, pages 108233.
Crossref
Crossref
Xiangxiang Zeng, Siyi Zhu, Weiqiang Lu, Zehui Liu, Jin Huang, Yadi Zhou, Jiansong Fang, Yin Huang, Huimin Guo, Lang Li, Bruce D. Trapp, Ruth Nussinov, Charis Eng, Joseph Loscalzo & Feixiong Cheng. (2020) Target identification among known drugs by deep learning from heterogeneous networks. Chemical Science 11:7, pages 1775-1797.
Crossref
Crossref
Matthew D. Coates, Kent E. Vrana & Victor Ruiz‐Velasco. (2018) The influence of voltage‐gated sodium channels on human gastrointestinal nociception. Neurogastroenterology & Motility 31:2, pages e13460.
Crossref
Crossref
Afrin Kamal & Mark Pimentel. (2018) Influence of Dietary Restriction on Irritable Bowel Syndrome. American Journal of Gastroenterology 114:2, pages 212-220.
Crossref
Crossref
Afrin Kamal, Ruthvik Padival & Bret Lashner. (2018) Inflammatory Bowel Disease and Irritable Bowel Syndrome: What to Do When There Is an Overlap. Inflammatory Bowel Diseases 24:12, pages 2479-2482.
Crossref
Crossref
Gregory S. Sayuk & C. Prakash Gyawali. (2015) Irritable Bowel Syndrome: Modern Concepts and Management Options. The American Journal of Medicine 128:8, pages 817-827.
Crossref
Crossref
Daniel Hoyer. 2015. Antitargets and Drug Safety. Antitargets and Drug Safety
57
80
.
E. Shah & M. Pimentel. (2014) Evaluating the functional net value of pharmacologic agents in treating irritable bowel syndrome. Alimentary Pharmacology & Therapeutics 39:9, pages 973-983.
Crossref
Crossref
Supriya Rao & H. Christian Weber. (2014) New treatment targets for the management of irritable bowel syndrome. Current Opinion in Endocrinology, Diabetes & Obesity 21:1, pages 9-14.
Crossref
Crossref
Kenneth Tong, Jean Paul Nicandro, Reshma Shringarpure, Emil Chuang & Lin Chang. (2013) A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Therapeutic Advances in Gastroenterology 6:5, pages 344-357.
Crossref
Crossref
Stacy Menees, Richard Saad & William D. Chey. (2012) Agents that act luminally to treat diarrhoea and constipation. Nature Reviews Gastroenterology & Hepatology 9:11, pages 661-674.
Crossref
Crossref
Eli D Ehrenpreis, Arthur A Ciociola & Prasad M Kulkarni. (2012) How the FDA Manages Drug Safety With Black Box Warnings, Use Restrictions, and Drug Removal, With Attention to Gastrointestinal Medications. American Journal of Gastroenterology 107:4, pages 501-504.
Crossref
Crossref
Nathan J. RogersShaker A. Mousa. (2012) The Shortcomings of Clinical Trials Assessing the Efficacy of Probiotics in Irritable Bowel Syndrome. The Journal of Alternative and Complementary Medicine 18:2, pages 112-119.
Crossref
Crossref
Lucinda A. Harris & Margaret M. Heitkemper. (2012) Practical Considerations for Recognizing and Managing Severe Irritable Bowel Syndrome. Gastroenterology Nursing 35:1, pages 12-21.
Crossref
Crossref
James H. Lewis. (2011) The Risk of Ischaemic Colitis in Irritable Bowel Syndrome Patients Treated with Serotonergic Therapies. Drug Safety 34:7, pages 545-565.
Crossref
Crossref
Xiangxiang Zeng, Siyi Zhu, Weiqiang Lu, Jin Huang, Zehui Liu, Yadi Zhou, Yuan Hou, Yin Huang, Huimin Guo, Jiansong Fang, Mingyao Liu, Bruce Trapp, Lang Li, Ruth Nussinov, Charis Eng, Joseph Loscalzo & Feixiong Cheng. (2019) Target Identification Among Known Drugs by Deep Learning from Heterogeneous Networks. SSRN Electronic Journal.
Crossref
Crossref